
ResMed (RMD) · Medical Devices
ResMed Q4 FY2026 earnings: summary, key numbers & outlook
Results filed 6 Aug 2026 · Quarter ended 30 Jun 2026
Press release ↗Investor relations ↗
Summaries and transcripts are machine-generated and can contain errors.
In brief
ResMed completed its Noctrix Health acquisition for restless legs wearables, agreed to sell MatrixCare, and partnered with ŌURA while launching AirSense 11 in Taiwan.
ResMed ended fiscal 2026 with demand strong across sleep devices, masks, accessories and software. Americas and Rest of World sleep businesses both grew, while Residential Care Software grew only modestly. It completed the Noctrix Health acquisition, which adds an FDA De Novo classified wearable therapy for Restless Leg Syndrome, and partnered with ŌURA on sleep health education and pathways to care.
Management says it will use its global scale and enhance its digital capabilities to improve patient outcomes and reduce healthcare costs. The portfolio is being narrowed: the MatrixCare business is being sold, with closing expected in the first quarter of fiscal 2027. The main risk is execution: integrating a new device category while a $42 million Astral field safety notification shows quality issues can carry costs.
Key numbers
- Q4 revenue · GAAP
- $1.5B
- Q4 net income · GAAP
- $383.0M
- Q4 diluted EPS · GAAP
- $2.64
- Q4 non-GAAP diluted EPS · non-GAAP
- $2.95
- Q4 gross margin · GAAP
- 58.8%
- Q4 non-GAAP gross margin · non-GAAP
- 62.3%
- Q4 income from operations · GAAP
- $449.0M
- Q4 operating margin · GAAP
- 30.7%
up 9% from a year ago
up 1% from a year ago
up 2% from a year ago
up 16% from a year ago
down 200 bps from a year ago
up 90 bps from a year ago
down 1% from a year ago
down 300 bps from a year ago
| Segment or metric | Value | Change |
|---|---|---|
| Americas Sleep and Breathing Health | $853.0M | up 8% |
| Rest of World Sleep and Breathing Health | $439.0M | up 13%, up 10% in constant currency |
| Total devices | $750.0M | up 8%, up 7% in constant currency |
| Masks and other | $542.0M | up 11%, up 10% in constant currency |
| Residential Care Software | $172.0M | up 3%, up 2% in constant currency |
Where each number comes from
- Q4 revenue: “Revenue | $1,464 | $1,348 | 9% | 8% Gross margin | 58.8% | 60.8% | (200) bps Non-GAAP gross margin (B) | 62.3% | 61.4% | 90 bps”
- Q4 net income: “Operating margin | 30.7% | 33.7% | (300) bps Non-GAAP income from operations (B) | 515 | 476 | 8 Non-GAAP operating margin | 35.2% | 35.3% | (10) bps Net income | 383 | 380 | 1”
- Q4 diluted EPS: “Non-GAAP net income (B) | 428 | 375 | 14 Diluted earnings per share | $2.64 | $2.58 | 2 Non-GAAP diluted earnings per share (B) | $2.95 | $2.55 | 16”
- Q4 non-GAAP diluted EPS: “Diluted earnings per share | $2.64 | $2.58 | 2 Non-GAAP diluted earnings per share (B) | $2.95 | $2.55 | 16 Operating cash flow | 455 | 539 | (16)”
- Q4 gross margin: “Revenue | $1,464 | $1,348 | 9% | 8% Gross margin | 58.8% | 60.8% | (200) bps Non-GAAP gross margin (B) | 62.3% | 61.4% | 90 bps”
- Q4 non-GAAP gross margin: “Gross margin | 58.8% | 60.8% | (200) bps Non-GAAP gross margin (B) | 62.3% | 61.4% | 90 bps Research and development expenses | 106 | 86 | 22 | 19”
- Q4 income from operations: “Non-GAAP selling, general, and administrative expenses(B) | 291 | 265 | 10 | 7 Income from operations | 449 | 455 | (1) Operating margin | 30.7% | 33.7% | (300) bps”
- Q4 operating margin: “Income from operations | 449 | 455 | (1) Operating margin | 30.7% | 33.7% | (300) bps Non-GAAP income from operations (B) | 515 | 476 | 8”
- Americas Sleep and Breathing Health: “Masks and other | 394 | 359 | 10 Total Americas (C) | $853 | $792 | 8 Rest of World (C) Devices | $291 | $261 | 12% | 9%”
- Rest of World Sleep and Breathing Health: “Masks and other | 148 | 128 | 16 | 12 Total Rest of World (C) | $439 | $389 | 13 | 10 Global revenue Total Devices”
- Total devices: “Global revenue Total Devices | $750 | $694 | 8% | 7% Total Masks and other | 542 | 487 | 11 | 10 Total Sleep and Breathing Health”
- Masks and other: “Total Devices | $750 | $694 | 8% | 7% Total Masks and other | 542 | 487 | 11 | 10 Total Sleep and Breathing Health | $1,292 | $1,181 | 9 | 8”
- Residential Care Software: “Total Sleep and Breathing Health | $1,292 | $1,181 | 9 | 8 Residential Care Software | 172 | 167 | 3 | 2 Total | $1,464 | $1,348 | 9 | 8”
Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.
| From the filing | Q4 FY2026 | vs year ago | vs last quarter |
|---|---|---|---|
| Revenue | $1.5B | +8.6% | +2.3% |
| Operating income | $448.7M | −1.3% | −10.2% |
| Net income | $383.4M | +1.0% | −3.8% |
| Free cash flow | $403.5M | −20.6% | −22.5% |
| Gross margin | 58.8% | −2.0 pts | −3.4 pts |
| Operating margin | 30.7% | −3.0 pts | −4.2 pts |
Calculated by code from XBRL, not by the model.
Outlook
| Metric | Period | Outlook |
|---|---|---|
| Capital to be returned to shareholders | fiscal year 2027 | more than $1.85 billion |
Key takeaways
Noctrix deal extends ResMed beyond sleep apnea
ResMed completed the acquisition of Noctrix Health, which sells FDA De Novo classified wearable therapeutics for Restless Leg Syndrome. This adds a new condition and device category to its home-care portfolio.
MatrixCare sale narrows the software portfolio
ResMed agreed to sell its MatrixCare business, with closing expected in the first quarter of fiscal 2027. Residential Care Software grew only 2% in constant currency, so the sale points to a sharper focus on sleep and breathing health.
ŌURA partnership targets sleep care pathways
ResMed partnered with ŌURA to expand access to sleep health education and pathways to care. It is a consumer-facing route to bring more people into diagnosis and treatment.
Masks and accessories outgrew devices
Masks and other grew 10% in constant currency against 7% for devices. Demand was described as strong across devices, masks, accessories and software.
Astral safety notification shows a quality cost
ResMed booked $42 million of Astral field safety notification expenses, which is the main reason GAAP gross margin of 58.8% trailed non-GAAP gross margin of 62.3%. It shows product-quality events can affect profitability even as productivity gains continue.
Charts
Fourth quarter worked out from the annual figure.
Data
| Q2 FY25 | $1.3B |
| Q3 FY25 | $1.3B |
| Q4 FY25 | $1.3B * |
| Q1 FY26 | $1.3B |
| Q2 FY26 | $1.4B |
| Q3 FY26 | $1.4B |
| Q4 FY26 | $1.5B * |
| Q1 FY27 | $1.4B |
Data
| Q2 FY25 | $2.34 |
| Q3 FY25 | $2.48 |
| Q1 FY26 | $2.37 |
| Q2 FY26 | $2.68 |
| Q3 FY26 | $2.74 |
| Q1 FY27 | $2.92 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q2 FY25 | 32.5% |
| Q3 FY25 | 33.0% |
| Q4 FY25 | 33.7% |
| Q1 FY26 | 33.4% |
| Q2 FY26 | 34.6% |
| Q3 FY26 | 34.9% |
| Q4 FY26 | 30.7% |
| Q1 FY27 | 32.0% |
Data
| Q2 FY25 | $288.0M |
| Q3 FY25 | $557.9M |
| Q4 FY25 | $508.2M |
| Q1 FY26 | $414.4M |
| Q2 FY26 | $311.2M |
| Q3 FY26 | $520.5M |
| Q4 FY26 | $403.5M |
| Q1 FY27 | $373.7M |
Operating cash flow minus capital expenditure, from cash flow statements.
Questions
What did ResMed do to expand its product portfolio this quarter?
It completed the acquisition of Noctrix Health, which sells FDA De Novo classified wearable therapeutics for Restless Leg Syndrome. It also launched AirCurve 11 ST/ST-A in the U.S. and AirTouch F30i Comfort in Brazil and Chile.
What is happening to ResMed's MatrixCare business?
ResMed agreed to sell MatrixCare, with the transaction expected to close in the first quarter of its fiscal year 2027.
Where is ResMed expanding AirSense 11?
It launched AirSense 11 in Taiwan, following other launches in APAC, EMEA and the Americas.
Why did ResMed partner with ŌURA?
The partnership aims to expand access to sleep health education and pathways to care, helping more people sleep better and improve their overall health.
Which parts of the business grew fastest in the quarter?
In constant currency, Rest of World Sleep and Breathing Health grew 10% and masks and other grew 10%, while Residential Care Software grew 2%.
Documents
From ResMed investor relations
SEC filing